Vol. 22/No. 10 | OncologyLive

Oncology Biosimilar Market Is Growing

May 20, 2021

Feature Article

Although the United States is behind Europe in terms of biosimilars approved and launched, the FDA is adding more approvals each year—29 since 2014—and 73 additional biosimilar candidates are in clinical trials and/or under FDA review.

Physician Confidence in Biosimilars Rests on Real-world Data

May 19, 2021

Providers and health care institutions want more real-world data on how patients respond to various biosimilar products, according to a varied panel of private practice, academic hospital, and group purchasing organization experts in a discussion at the Community Oncology Alliance virtual 2021 Community Oncology Conference in April.

The Chance to Make a Difference Made Herbst a Lung Cancer Pioneer

May 18, 2021

Roy S. Herbst, MD, PhD, was inspired to become an oncologist during his first week as an MD/PhD candidate at Cornell University and The Rockefeller University, thanks in part to Ralph L. Nachman, MD, longtime chair of Weill Department of Medicine at Weill Cornell Medical College.

Long-Term Neoadjuvant Study Tests Nivolumab in ER+/HER2- Breast Cancer

May 17, 2021

Investigators are evaluating the addition of nivolumab to standard neoadjuvant therapy in patients with high-risk, estrogen-receptor–positive/ HER2-negative breast cancer to determine whether the PD-1 immune checkpoint inhibitor can improve recurrence rates.

Reaching Conclusions From Limited Data Holds Pitfalls

May 13, 2021

From the Editor

The challenges of assessing COVID-19 vaccines shows that events in the real world may differ from those of a formal objective scientific analysis, especially in a setting where such evaluations of necessity involve very small numbers.